From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
Number of patients (%)
Time from randomization
DD/DI arm (N = 86)
HDI arm(N = 80)
Induction
56
(65)
52
3 months
35
(49)
42
(64)
5 months
25
(42)
33
(55)
7 months
20
(36)
23
(43)